Piperilate, also known as Pipethanate, is a hetrazepine derivative PAF antagonist and anticholinergic mixture, commonly utilized in bronchial asthma research. This compound exhibits hypotensive properties and has been found to effectively counteract the toxic effects of organophosphates in mice [1] [2] [3].

Piperilate (11.3 mg/kg, 29.42 mg/kg; i.p.; single dose) shows anticholinergic activity, and (30 mg/kg; i.p.; single dose) exerts efficacy in mice poisoned by the organophosphates [1]. Piperilate (1 mg/kg; i.v.) causes hypotension in rabbit which is not blocked by dichloroisoproterenol or Atropine [2]. Piperilate (3 mg/kg; i.v.) decreases respiration and heart rate of test rabbits, blocks the Adrenaline -induced constriction of an isolated rabbit auricle preparation [2]. Animal Model: Male albino mice (18-22 g) [1] Dosage: 11.3 mg/kg, 29.42 mg/kg Administration: Intraperitoneal injection; single dose Result: Showed anticholinergic activity with EC 50 values of 11.33 mg/kg (antagonism of oxotremorine induced salivation) and 29.42 mg/kg (antagonism of oxotremorine induced tremor) in mice.